Get the Stockscreener App
40.09
2.85%
1.11
Pre-market:
39.92
-0.17
-0.42%
Mbx Biosciences Inc stock is traded at $40.09, with a volume of 1.14M.
It is up +2.85% in the last 24 hours and up +23.54% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$38.98
Open:
$39.05
24h Volume:
1.14M
Relative Volume:
1.80
Market Cap:
$1.91B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-16.57
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
+34.21%
1M Performance:
+23.54%
6M Performance:
+44.47%
1Y Performance:
+281.81%
1-Day Range:
$37.84
$42.08
1-Week Range:
$29.20
$42.08
52-Week Range:
$9.43
$45.85
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
40.09 | 1.86B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences shares fall despite positive one-year trial results for Canvuparatide (MBX) - MSN
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? - Yahoo Finance
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Health Care Roundup: Market Talk - Moomoo
MBX News | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) Share Price, MBX Stock News, MBX Share Price & Updates - Kalkine
Mbx Biosciences90% of Patients in Ole Rema - Moomoo
MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk - Moomoo
Street canvu MBX phase II HP data more than one way - BioWorld News
MBX: Once-weekly kanvuparatide maintained durable efficacy and safety at one year, supporting phase III plans - TradingView
MBX reports one-year data for hypoparathyroidism drug candidate - Investing.com UK
MBX updates trial data for hypoparathyroidism drug (MBX:NASDAQ) - Seeking Alpha
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly CanvuparatideSlideshow (NASDAQ:MBX) 2026-06-12 - Seeking Alpha
Transcript : MBX Biosciences, Inc.Special Call - marketscreener.com
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) - Yahoo Finance
MBX Biosciences reports positive one-year canvuparatide data - grafa.com
MBX Biosciences stock falls despite one-year drug trial data - Investing.com UK
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell - marketscreener.com
MBX reports one-year data for hypoparathyroidism drug candidate By Investing.com - Investing.com Canada
MBX: Once-weekly canvuparatide maintained efficacy and safety at one year in chronic HP patients - TradingView
MBX Biosciences (Nasdaq: MBX) touts one-year canvuparatide data, plans Phase 3 - Stock Titan
Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism - TradingView
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism - The Manila Times
Once-weekly PTH drug from MBX maintained calcium and kidney measures for a year - Stock Titan
Richard B. Bartram (MBX) plans sale of 9,167 shares after option exercise - Stock Titan
MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan
MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike - Stock Titan
MBX Biosciences, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Registration on NASDAQ - Minichart
MBX Biosciences Shareholders Approve Directors and Auditor - TipRanks
MBX Biosciences: In Danger Of Being Outpaced By RivalsRating Downgrade (NASDAQ:MBX) - Seeking Alpha
MB elects two Class II directors to three-year terms through 2029 - TradingView
MBX Biosciences (MBX) grants stock options to director Ora Pescovitz - Stock Titan
MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant - Stock Titan
MBX Biosciences (MBX) director receives stock options for 12,500 shares - Stock Titan
MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91 - Stock Titan
MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options - Stock Titan
MBX Biosciences (MBX) director awarded 12,500 stock options - Stock Titan
MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young - Stock Titan
Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - Sahm
MBX: Once-weekly PTH and monthly obesity therapies show strong promise for efficacy, tolerability, and market impact - TradingView
MBX Biosciences, Inc. partners with HypoPARAassoc to advance treatment for over 100,000 hypoparathyroidism patients in U.S. - Traders Union
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 - The Manila Times
MBX Biosciences to host webcast on Phase 2 trial results of once-weekly canvuparatide at ENDO 2026 - Pluang
Number of shareholders of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - AOL.com
3 Overlooked Stocks Set to Soar in 2026 - AOL.com
MBX Biosciences, Inc. executives to update on endocrine and metabolic disorder treatment advancements in New York - Traders Union
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - GlobeNewswire
MBX Biosciences Inc Share News (MBX) - Investing.com India
MBX Biosciences Inc. (MBX) Q1 2026 Earnings: EPS Beat as Pre-Revenue Biotech Advances PipelineProfit Warning Alert - Newser
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):